Trial Profile
A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs MK 3577 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Nov 2019 According to EudraCT Record this trial has been completed in Germany location although I have retained the status as per NCT
- 13 Jan 2017 Treatment arm has been changed from 5 to 14 and trial focus has been changed from TU to TU and AR.
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.